CaiCai99的个人主页 - 老虎社区

CaiCai99

CaiCai99

暂无个人介绍

IP属地：未知

295关注

5粉丝

0主题

0勋章

2021-10-30

[Great] [Great]

抱歉，原内容已删除

2021-11-14

[Surprised] [Surprised]

抱歉，原内容已删除

2021-11-13

[Miser] [Miser]

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>

2021-11-09

[Surprised] [Surprised]

Short squeezes are pushing these stocks to the moon<blockquote>轧空正在将这些股票推向月球</blockquote>

2021-05-29

Interesting

抱歉，原内容已删除

2021-11-20

[Happy] [Happy]

抱歉，原内容已删除

2021-10-31

[Anger] [Anger]

抱歉，原内容已删除

2021-10-17

Interesting

Plug Power's Lowered Guidance Lacking Detail, Analyst Says<blockquote>分析师称普拉格能源下调指引缺乏细节</blockquote>

2021-06-29

Interesting

抱歉，原内容已删除

2021-06-22

Like and comment

Chicken producer Sanderson Farms explores sale<blockquote>鸡肉生产商桑德森农场探索出售</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3577149952498564","uuid":"3577149952498564","gmtCreate":1614055928975,"gmtModify":1634261852178,"name":"CaiCai99","pinyin":"caicai99","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":295,"tweetSize":43,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":608984536,"gmtCreate":1638596794430,"gmtModify":1638596794492,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Surprised]&nbsp;[Surprised]&nbsp;","listText":"[Surprised]&nbsp;[Surprised]&nbsp;","text":"[Surprised] [Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608984536","repostId":"2188853578","repostType":4,"isVote":1,"tweetType":1,"viewCount":3133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608984600,"gmtCreate":1638596755121,"gmtModify":1638596755121,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[What]&nbsp;[Miser]&nbsp;","listText":"[What]&nbsp;[Miser]&nbsp;","text":"[What] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608984600","repostId":"601891577","repostType":1,"repost":{"id":601891577,"gmtCreate":1638504689496,"gmtModify":1638525206259,"author":{"id":"3527667583497005","authorId":"3527667583497005","name":"期权异动观察","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667583497005","idStr":"3527667583497005"},"themes":[],"title":"12.3期权异动观察，中概股继续暴跌","htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a> <a target=\"_blank\" href=\"https://laohu8.com/OPT/AMC%2020211203%2030.0%20CALL\">&nbsp;$AMC 20211203 30.0 CALL$</a>继昨日期权异动后，今日期权再次异动，盘中波动非常大，如果短线不能有效企稳，下跌空间会非常大。 <a href=\"https://laohu8.com/S/BHC\">$Bausch Health Companies Inc(BHC)$</a>&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/OPT/BHC%2020220414%2027.0%20CALL\">$BHC 20220414 27.0 CALL$</a>经过连续多日下跌之后，昨日出现了小幅度反弹，看空为主。 <a href=\"https://laohu8.com/S/GGPI\">$Gores Guggenheim Inc(GGPI)$</a> <a target=\"_blank\" href=\"https://laohu8.com/OPT/GGPI%2020230120%2025.0%20CALL\">&nbsp;$GGPI 20230120 25.0 CALL$</a>基本面无异动，股价在20日线附近的支撑几乎被打破，后续看能否有新的支撑位出现，短线看空为主。 <a href=\"https://laohu8.com/S/DKNG\">$DraftKings Inc.(DKNG)$</a> &nbsp;&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a> <a target=\"_blank\" href=\"https://laohu8.com/OPT/AMC%2020211203%2030.0%20CALL\">&nbsp;$AMC 20211203 30.0 CALL$</a>继昨日期权异动后，今日期权再次异动，盘中波动非常大，如果短线不能有效企稳，下跌空间会非常大。 <a href=\"https://laohu8.com/S/BHC\">$Bausch Health Companies Inc(BHC)$</a>&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/OPT/BHC%2020220414%2027.0%20CALL\">$BHC 20220414 27.0 CALL$</a>经过连续多日下跌之后，昨日出现了小幅度反弹，看空为主。 <a href=\"https://laohu8.com/S/GGPI\">$Gores Guggenheim Inc(GGPI)$</a> <a target=\"_blank\" href=\"https://laohu8.com/OPT/GGPI%2020230120%2025.0%20CALL\">&nbsp;$GGPI 20230120 25.0 CALL$</a>基本面无异动，股价在20日线附近的支撑几乎被打破，后续看能否有新的支撑位出现，短线看空为主。 <a href=\"https://laohu8.com/S/DKNG\">$DraftKings Inc.(DKNG)$</a> &nbsp;&nbsp;","text":"$AMC院线(AMC)$ $AMC 20211203 30.0 CALL$继昨日期权异动后，今日期权再次异动，盘中波动非常大，如果短线不能有效企稳，下跌空间会非常大。 $Bausch Health Companies Inc(BHC)$ $BHC 20220414 27.0 CALL$经过连续多日下跌之后，昨日出现了小幅度反弹，看空为主。 $Gores Guggenheim Inc(GGPI)$ $GGPI 20230120 25.0 CALL$基本面无异动，股价在20日线附近的支撑几乎被打破，后续看能否有新的支撑位出现，短线看空为主。 $DraftKings Inc.(DKNG)$","images":[{"img":"https://static.tigerbbs.com/71f472f30795deea1bc9dc6696fcd6c4","width":"-1","height":"-1"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601891577","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2574,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600223357,"gmtCreate":1638160844812,"gmtModify":1638160844812,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Miser]&nbsp;[Miser]&nbsp;","listText":"[Miser]&nbsp;[Miser]&nbsp;","text":"[Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600223357","repostId":"1193409808","repostType":4,"isVote":1,"tweetType":1,"viewCount":3183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872101802,"gmtCreate":1637453789059,"gmtModify":1637453789139,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Grin]&nbsp;[Grin]&nbsp;","listText":"[Grin]&nbsp;[Grin]&nbsp;","text":"[Grin] [Grin]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872101802","repostId":"876277041","repostType":1,"repost":{"id":876277041,"gmtCreate":1637327655981,"gmtModify":1637377844933,"author":{"id":"9000000000000104","authorId":"9000000000000104","name":"小左第一视角","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"9000000000000104","idStr":"9000000000000104"},"themes":[],"title":"","htmlText":"\n \n \n  大型头肩底，抄底？半导体、科技股还得涨吗？NVDA又涨了？TSLA洗盘。\n \n","listText":"大型头肩底，抄底？半导体、科技股还得涨吗？NVDA又涨了？TSLA洗盘。","text":"大型头肩底，抄底？半导体、科技股还得涨吗？NVDA又涨了？TSLA洗盘。","images":[],"top":1,"highlighted":2,"essential":2,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876277041","isVote":1,"tweetType":2,"object":{"id":"6ed5c7bdfbd24f40adf8ce2b5ae84a4a","tweetId":"876277041","title":"大型头肩底，抄底？半导体、科技股还得涨吗？NVDA又涨了？TSLA洗盘。AAL、AI、AMZN、ASML、BABA、CRM、DIS、FB、HD、NIO、NVDA、QS、TSLA、TSM小左1119五","videoUrl":"http://v.tigerbbs.com/1637327646853e4b33b84e40912e7e141c1f542882b75.mp4","poster":"https://static.tigerbbs.com/b0dbd85e0fe64f0078ffb3370ca2ae45","shareLink":"http://v.tigerbbs.com/1637327646853e4b33b84e40912e7e141c1f542882b75.mp4"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872103137,"gmtCreate":1637453722736,"gmtModify":1637453722736,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Anger]&nbsp;[Anger]&nbsp;","listText":"[Anger]&nbsp;[Anger]&nbsp;","text":"[Anger] [Anger]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872103137","repostId":"2184384295","repostType":4,"isVote":1,"tweetType":1,"viewCount":3160,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872913922,"gmtCreate":1637389846629,"gmtModify":1637390296485,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Happy]&nbsp;[Happy]&nbsp;","listText":"[Happy]&nbsp;[Happy]&nbsp;","text":"[Happy] [Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872913922","repostId":"2184842262","repostType":4,"isVote":1,"tweetType":1,"viewCount":2006,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878289905,"gmtCreate":1637197235805,"gmtModify":1637197235805,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Miser]&nbsp;[Miser]&nbsp;","listText":"[Miser]&nbsp;[Miser]&nbsp;","text":"[Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878289905","repostId":"2184854899","repostType":4,"isVote":1,"tweetType":1,"viewCount":2296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873181408,"gmtCreate":1636883721018,"gmtModify":1636883721018,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Surprised]&nbsp;[Surprised]&nbsp;","listText":"[Surprised]&nbsp;[Surprised]&nbsp;","text":"[Surprised] [Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873181408","repostId":"1103944030","repostType":4,"isVote":1,"tweetType":1,"viewCount":2623,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879741980,"gmtCreate":1636779524101,"gmtModify":1636779524190,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Miser]&nbsp;[Miser]&nbsp;","listText":"[Miser]&nbsp;[Miser]&nbsp;","text":"[Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879741980","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2874,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870101955,"gmtCreate":1636591222312,"gmtModify":1636591222367,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Smile]&nbsp;[Smile]&nbsp;","listText":"[Smile]&nbsp;[Smile]&nbsp;","text":"[Smile] [Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870101955","repostId":"1129052107","repostType":4,"isVote":1,"tweetType":1,"viewCount":2134,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844842615,"gmtCreate":1636419001309,"gmtModify":1636419001466,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Surprised]&nbsp;[Surprised]&nbsp;","listText":"[Surprised]&nbsp;[Surprised]&nbsp;","text":"[Surprised] [Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/844842615","repostId":"1104683977","repostType":4,"repost":{"id":"1104683977","kind":"news","pubTimestamp":1636418694,"share":"https://www.laohu8.com/m/news/1104683977?lang=zh_CN&edition=full","pubTime":"2021-11-09 08:44","market":"us","language":"en","title":"Short squeezes are pushing these stocks to the moon<blockquote>轧空正在将这些股票推向月球</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1104683977","media":"CNN","summary":"New York (CNN Business)The individual investor army on Reddit that helped push GameStop and AMC to u","content":"<p><a href=\"https://laohu8.com/S/NWY\">New York</a> (CNN Business)The individual investor army on Reddit that helped push <a href=\"https://laohu8.com/S/GME\">GameStop</a> and AMC to unprecedented heights earlier this year has found some more companies to rally around.</p><p><blockquote><a href=\"https://laohu8.com/S/NWY\">纽约</a>（CNN商业）Reddit上的个人投资者大军帮助推动了<a href=\"https://laohu8.com/S/GME\">游戏驿站</a>今年早些时候，AMC达到了前所未有的高度，并找到了更多公司的支持。</blockquote></p><p> Several stocks that have enjoyed extraordinary pops lately, such as <a href=\"https://laohu8.com/S/CAR\">Avis Budget</a> (<a href=\"https://laohu8.com/S/00699\">CAR</a>) and Bed Bath &amp; Beyond (BBBY), have become so-called meme stocks that many professional investors have bet against ... and have gotten burned for because of what's known as a short squeeze.</p><p><blockquote>最近表现出色的几只股票，例如<a href=\"https://laohu8.com/S/CAR\">预算意见</a>(<a href=\"https://laohu8.com/S/00699\">车</a>）和Bed Bath&amp;Beyond(BBBY)已成为许多专业投资者做空的所谓模因股票……并因为所谓的空头挤压而被烧伤。</blockquote></p><p> Avis Budget reported solid earnings last week. But the strength of the stock's 108% surge the day after reporting results surprised many. Shares were up as much as 218% at <a href=\"https://laohu8.com/S/AONE.U\">one</a> point.</p><p><blockquote>Avis Budget上周公布了稳健的收益。但该股在公布业绩后第二天飙升108%，令许多人感到惊讶。股价上涨218%<a href=\"https://laohu8.com/S/AONE.U\">一</a>点。</blockquote></p><p> Bed Bath and Beyond skyrocketed nearly 50% in a matter of a few days last week after announcing a partnership to sell some of its products at grocery store chain <a href=\"https://laohu8.com/S/KR\">Kroger</a> (KR).</p><p><blockquote>Bed Bath and Beyond上周宣布合作在杂货店连锁店销售其部分产品后，股价在几天内飙升了近50%<a href=\"https://laohu8.com/S/KR\">克罗格</a>（KR）。</blockquote></p><p> Both Avis Budget and Bed Bath &amp; Beyond have something in common with AMC (AMC) and GameStop (GME).</p><p><blockquote>Avis Budget和Bed Bath&amp;Beyond都与AMC(AMC)和游戏驿站(GME)有一些共同点。</blockquote></p><p> All of these stocks, along with other meme darlings such as <a href=\"https://laohu8.com/S/BBRY\">BlackBerry</a> (BB), electric van maker <a href=\"https://laohu8.com/S/WKHS\">Workhorse</a> (WKHS) and cannabis company Sundial Growers (SNDL), have been targets of so-called short sellers.</p><p><blockquote>所有这些股票，以及其他迷因宠儿，例如<a href=\"https://laohu8.com/S/BBRY\">黑莓</a>(BB)，电动货车制造商<a href=\"https://laohu8.com/S/WKHS\">老黄牛</a>(WKHS)和大麻公司Sundial Growers(SNDL)一直是所谓卖空者的目标。</blockquote></p><p> More than 20% of the shares of Avis Budget and Bed Bath &amp; Beyond are being held by short sellers, aka shorts.</p><p><blockquote>Avis Budget和Bed Bath&amp;Beyond超过20%的股份由卖空者（又名空头）持有。</blockquote></p><p> Shorts, often big hedge funds and other large institutional firms, will borrow a stock and sell it with the hopes that the price will fall and they can buy it back for less. The short seller then pockets the difference between what they sold at and the repurchase price.</p><p><blockquote>空头，通常是大型对冲基金和其他大型机构公司，会借入股票并出售，希望价格会下跌，然后他们可以以更低的价格回购。然后，卖空者将出售价格与回购价格之间的差额收入囊中。</blockquote></p><p> So say a short sells a borrowed stock when it's trading at $20 and it falls to $10. If the short seller buys the stock back at $10 and returns it to the lender, they make a $10 profit. It's known as covering their short position.</p><p><blockquote>比方说，当一只借来的股票的交易价格为20美元，然后跌至10美元时，卖空者卖出了该股票。如果卖空者以10美元的价格回购股票并将其返还给贷方，他们将获得10美元的利润。这就是所谓的回补空头头寸。</blockquote></p><p> But here's where short sellers can run into trouble. If a stock that's being shorted starts to go up for some reason — such as a good earnings report or news of a strategic partnership — short sellers may be forced to buy back shares en masse or risk incurring massive losses.</p><p><blockquote>但这就是卖空者可能遇到麻烦的地方。如果被做空的股票由于某种原因（例如良好的收益报告或战略合作伙伴关系的消息）开始上涨，卖空者可能会被迫集体回购股票，否则可能会面临遭受巨大损失的风险。</blockquote></p><p> Back to the $20 short seller example, if the company reports good news and the stock goes up to $30, the short seller is looking at a potential $10 loss if they cover at the price. The losses increase as the stock heads higher. If it hits $40, that's a $20 loss, and so on — for every share they've shorted.</p><p><blockquote>回到20美元卖空者的例子，如果公司报告好消息并且股价上涨至30美元，那么卖空者如果按该价格回补，可能会损失10美元。随着股价走高，损失也会增加。如果价格达到40美元，他们每做空一股，就会损失20美元，依此类推。</blockquote></p><p> Plus, short sellers have to eventually return the shares they've borrowed. So if they wait too long to cover the short position, they could face major losses. The so-called apes on Reddit have figured this out.</p><p><blockquote>此外，卖空者最终必须归还他们借入的股票。因此，如果他们等待太久才回补空头头寸，他们可能会面临重大损失。Reddit上所谓的猿类已经明白了这一点。</blockquote></p><p> \"This is what a short squeeze looks like,\" wrote one Reddit user last week about Avis Budget. \"Good (nee, STELLAR) earnings caused sudden and hard upward price movement ... No recourse other than to cover.\"</p><p><blockquote>“这就是轧空的样子，”一位Reddit用户上周在谈到Avis Budget时写道。“良好的（nee，恒星）收益导致价格突然大幅上涨……除了弥补之外没有其他追索权。”</blockquote></p><p> That's why fans of stocks like GameStop, AMC and more recently Avis Budget and Bed Bath &amp; Beyond aggressively call for retail traders to start buying heavily shorted stocks to push them even higher.</p><p><blockquote>这就是为什么游戏驿站、AMC以及最近的Avis Budget和Bed Bath&amp;Beyond等股票的粉丝积极看涨期权，要求散户交易者开始购买严重做空的股票，以推高它们。</blockquote></p><p> They realize that they are inflicting damage on the short sellers by doing so. But that helps push the shares even higher since the short sellers have to start joining the buying frenzy too.</p><p><blockquote>他们意识到这样做是在给卖空者造成损害。但这有助于推高股价，因为卖空者也必须开始加入购买狂潮。</blockquote></p><p> \"Short Squeeze Stocks Season is Back!\" declared one poster on Reddit in a video last week, referring specifically to <a href=\"https://laohu8.com/S/BB\">BlackBerry</a>, Avis Budget, Bed Bath &amp; Beyond, AMC and GameStop.</p><p><blockquote>“逼空股票季节又回来了！”上周在Reddit上的一段视频中宣布了一张海报，特别是指<a href=\"https://laohu8.com/S/BB\">黑莓</a>、Avis Budget、Bed Bath&amp;Beyond、AMC和游戏驿站。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Short squeezes are pushing these stocks to the moon<blockquote>轧空正在将这些股票推向月球</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShort squeezes are pushing these stocks to the moon<blockquote>轧空正在将这些股票推向月球</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">CNN</strong><span class=\"h-time small\">2021-11-09 08:44</span>\n</p>\n</h4>\n</header>\n<article>\n<p><a href=\"https://laohu8.com/S/NWY\">New York</a> (CNN Business)The individual investor army on Reddit that helped push <a href=\"https://laohu8.com/S/GME\">GameStop</a> and AMC to unprecedented heights earlier this year has found some more companies to rally around.</p><p><blockquote><a href=\"https://laohu8.com/S/NWY\">纽约</a>（CNN商业）Reddit上的个人投资者大军帮助推动了<a href=\"https://laohu8.com/S/GME\">游戏驿站</a>今年早些时候，AMC达到了前所未有的高度，并找到了更多公司的支持。</blockquote></p><p> Several stocks that have enjoyed extraordinary pops lately, such as <a href=\"https://laohu8.com/S/CAR\">Avis Budget</a> (<a href=\"https://laohu8.com/S/00699\">CAR</a>) and Bed Bath &amp; Beyond (BBBY), have become so-called meme stocks that many professional investors have bet against ... and have gotten burned for because of what's known as a short squeeze.</p><p><blockquote>最近表现出色的几只股票，例如<a href=\"https://laohu8.com/S/CAR\">预算意见</a>(<a href=\"https://laohu8.com/S/00699\">车</a>）和Bed Bath&amp;Beyond(BBBY)已成为许多专业投资者做空的所谓模因股票……并因为所谓的空头挤压而被烧伤。</blockquote></p><p> Avis Budget reported solid earnings last week. But the strength of the stock's 108% surge the day after reporting results surprised many. Shares were up as much as 218% at <a href=\"https://laohu8.com/S/AONE.U\">one</a> point.</p><p><blockquote>Avis Budget上周公布了稳健的收益。但该股在公布业绩后第二天飙升108%，令许多人感到惊讶。股价上涨218%<a href=\"https://laohu8.com/S/AONE.U\">一</a>点。</blockquote></p><p> Bed Bath and Beyond skyrocketed nearly 50% in a matter of a few days last week after announcing a partnership to sell some of its products at grocery store chain <a href=\"https://laohu8.com/S/KR\">Kroger</a> (KR).</p><p><blockquote>Bed Bath and Beyond上周宣布合作在杂货店连锁店销售其部分产品后，股价在几天内飙升了近50%<a href=\"https://laohu8.com/S/KR\">克罗格</a>（KR）。</blockquote></p><p> Both Avis Budget and Bed Bath &amp; Beyond have something in common with AMC (AMC) and GameStop (GME).</p><p><blockquote>Avis Budget和Bed Bath&amp;Beyond都与AMC(AMC)和游戏驿站(GME)有一些共同点。</blockquote></p><p> All of these stocks, along with other meme darlings such as <a href=\"https://laohu8.com/S/BBRY\">BlackBerry</a> (BB), electric van maker <a href=\"https://laohu8.com/S/WKHS\">Workhorse</a> (WKHS) and cannabis company Sundial Growers (SNDL), have been targets of so-called short sellers.</p><p><blockquote>所有这些股票，以及其他迷因宠儿，例如<a href=\"https://laohu8.com/S/BBRY\">黑莓</a>(BB)，电动货车制造商<a href=\"https://laohu8.com/S/WKHS\">老黄牛</a>(WKHS)和大麻公司Sundial Growers(SNDL)一直是所谓卖空者的目标。</blockquote></p><p> More than 20% of the shares of Avis Budget and Bed Bath &amp; Beyond are being held by short sellers, aka shorts.</p><p><blockquote>Avis Budget和Bed Bath&amp;Beyond超过20%的股份由卖空者（又名空头）持有。</blockquote></p><p> Shorts, often big hedge funds and other large institutional firms, will borrow a stock and sell it with the hopes that the price will fall and they can buy it back for less. The short seller then pockets the difference between what they sold at and the repurchase price.</p><p><blockquote>空头，通常是大型对冲基金和其他大型机构公司，会借入股票并出售，希望价格会下跌，然后他们可以以更低的价格回购。然后，卖空者将出售价格与回购价格之间的差额收入囊中。</blockquote></p><p> So say a short sells a borrowed stock when it's trading at $20 and it falls to $10. If the short seller buys the stock back at $10 and returns it to the lender, they make a $10 profit. It's known as covering their short position.</p><p><blockquote>比方说，当一只借来的股票的交易价格为20美元，然后跌至10美元时，卖空者卖出了该股票。如果卖空者以10美元的价格回购股票并将其返还给贷方，他们将获得10美元的利润。这就是所谓的回补空头头寸。</blockquote></p><p> But here's where short sellers can run into trouble. If a stock that's being shorted starts to go up for some reason — such as a good earnings report or news of a strategic partnership — short sellers may be forced to buy back shares en masse or risk incurring massive losses.</p><p><blockquote>但这就是卖空者可能遇到麻烦的地方。如果被做空的股票由于某种原因（例如良好的收益报告或战略合作伙伴关系的消息）开始上涨，卖空者可能会被迫集体回购股票，否则可能会面临遭受巨大损失的风险。</blockquote></p><p> Back to the $20 short seller example, if the company reports good news and the stock goes up to $30, the short seller is looking at a potential $10 loss if they cover at the price. The losses increase as the stock heads higher. If it hits $40, that's a $20 loss, and so on — for every share they've shorted.</p><p><blockquote>回到20美元卖空者的例子，如果公司报告好消息并且股价上涨至30美元，那么卖空者如果按该价格回补，可能会损失10美元。随着股价走高，损失也会增加。如果价格达到40美元，他们每做空一股，就会损失20美元，依此类推。</blockquote></p><p> Plus, short sellers have to eventually return the shares they've borrowed. So if they wait too long to cover the short position, they could face major losses. The so-called apes on Reddit have figured this out.</p><p><blockquote>此外，卖空者最终必须归还他们借入的股票。因此，如果他们等待太久才回补空头头寸，他们可能会面临重大损失。Reddit上所谓的猿类已经明白了这一点。</blockquote></p><p> \"This is what a short squeeze looks like,\" wrote one Reddit user last week about Avis Budget. \"Good (nee, STELLAR) earnings caused sudden and hard upward price movement ... No recourse other than to cover.\"</p><p><blockquote>“这就是轧空的样子，”一位Reddit用户上周在谈到Avis Budget时写道。“良好的（nee，恒星）收益导致价格突然大幅上涨……除了弥补之外没有其他追索权。”</blockquote></p><p> That's why fans of stocks like GameStop, AMC and more recently Avis Budget and Bed Bath &amp; Beyond aggressively call for retail traders to start buying heavily shorted stocks to push them even higher.</p><p><blockquote>这就是为什么游戏驿站、AMC以及最近的Avis Budget和Bed Bath&amp;Beyond等股票的粉丝积极看涨期权，要求散户交易者开始购买严重做空的股票，以推高它们。</blockquote></p><p> They realize that they are inflicting damage on the short sellers by doing so. But that helps push the shares even higher since the short sellers have to start joining the buying frenzy too.</p><p><blockquote>他们意识到这样做是在给卖空者造成损害。但这有助于推高股价，因为卖空者也必须开始加入购买狂潮。</blockquote></p><p> \"Short Squeeze Stocks Season is Back!\" declared one poster on Reddit in a video last week, referring specifically to <a href=\"https://laohu8.com/S/BB\">BlackBerry</a>, Avis Budget, Bed Bath &amp; Beyond, AMC and GameStop.</p><p><blockquote>“逼空股票季节又回来了！”上周在Reddit上的一段视频中宣布了一张海报，特别是指<a href=\"https://laohu8.com/S/BB\">黑莓</a>、Avis Budget、Bed Bath&amp;Beyond、AMC和游戏驿站。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://edition.cnn.com/2021/11/08/investing/short-squeeze-stocks/index.html\">CNN</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CAR":"安飞士","KR":"克罗格","BBBY":"Bed Bath & Beyond, Inc.","GME":"游戏驿站","AMC":"AMC院线"},"source_url":"https://edition.cnn.com/2021/11/08/investing/short-squeeze-stocks/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104683977","content_text":"New York (CNN Business)The individual investor army on Reddit that helped push GameStop and AMC to unprecedented heights earlier this year has found some more companies to rally around.\nSeveral stocks that have enjoyed extraordinary pops lately, such as Avis Budget (CAR) and Bed Bath & Beyond (BBBY), have become so-called meme stocks that many professional investors have bet against ... and have gotten burned for because of what's known as a short squeeze.\nAvis Budget reported solid earnings last week. But the strength of the stock's 108% surge the day after reporting results surprised many. Shares were up as much as 218% at one point.\nBed Bath and Beyond skyrocketed nearly 50% in a matter of a few days last week after announcing a partnership to sell some of its products at grocery store chain Kroger (KR).\nBoth Avis Budget and Bed Bath & Beyond have something in common with AMC (AMC) and GameStop (GME).\nAll of these stocks, along with other meme darlings such as BlackBerry (BB), electric van maker Workhorse (WKHS) and cannabis company Sundial Growers (SNDL), have been targets of so-called short sellers.\nMore than 20% of the shares of Avis Budget and Bed Bath & Beyond are being held by short sellers, aka shorts.\nShorts, often big hedge funds and other large institutional firms, will borrow a stock and sell it with the hopes that the price will fall and they can buy it back for less. The short seller then pockets the difference between what they sold at and the repurchase price.\nSo say a short sells a borrowed stock when it's trading at $20 and it falls to $10. If the short seller buys the stock back at $10 and returns it to the lender, they make a $10 profit. It's known as covering their short position.\nBut here's where short sellers can run into trouble. If a stock that's being shorted starts to go up for some reason — such as a good earnings report or news of a strategic partnership — short sellers may be forced to buy back shares en masse or risk incurring massive losses.\nBack to the $20 short seller example, if the company reports good news and the stock goes up to $30, the short seller is looking at a potential $10 loss if they cover at the price. The losses increase as the stock heads higher. If it hits $40, that's a $20 loss, and so on — for every share they've shorted.\nPlus, short sellers have to eventually return the shares they've borrowed. So if they wait too long to cover the short position, they could face major losses. The so-called apes on Reddit have figured this out.\n\"This is what a short squeeze looks like,\" wrote one Reddit user last week about Avis Budget. \"Good (nee, STELLAR) earnings caused sudden and hard upward price movement ... No recourse other than to cover.\"\nThat's why fans of stocks like GameStop, AMC and more recently Avis Budget and Bed Bath & Beyond aggressively call for retail traders to start buying heavily shorted stocks to push them even higher.\nThey realize that they are inflicting damage on the short sellers by doing so. But that helps push the shares even higher since the short sellers have to start joining the buying frenzy too.\n\"Short Squeeze Stocks Season is Back!\" declared one poster on Reddit in a video last week, referring specifically to BlackBerry, Avis Budget, Bed Bath & Beyond, AMC and GameStop.","news_type":1,"symbols_score_info":{"GME":0.9,"AMC":0.9,"CAR":0.9,"KR":0.9,"BBBY":0.9}},"isVote":1,"tweetType":1,"viewCount":861,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845609790,"gmtCreate":1636332226374,"gmtModify":1636332310504,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Smile]&nbsp;[Smile]&nbsp;","listText":"[Smile]&nbsp;[Smile]&nbsp;","text":"[Smile] [Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845609790","repostId":"2181284457","repostType":4,"isVote":1,"tweetType":1,"viewCount":619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841888306,"gmtCreate":1635901304125,"gmtModify":1635901304187,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Great]&nbsp;[Great]&nbsp;","listText":"[Great]&nbsp;[Great]&nbsp;","text":"[Great] [Great]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841888306","repostId":"1166690474","repostType":4,"repost":{"id":"1166690474","kind":"news","pubTimestamp":1635899343,"share":"https://www.laohu8.com/m/news/1166690474?lang=zh_CN&edition=full","pubTime":"2021-11-03 08:29","market":"us","language":"en","title":"JPMorgan to restrict trading of some U.S. cannabis stocks<blockquote>摩根大通将限制部分美国大麻股票的交易</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1166690474","media":"Reuters","summary":"Nov 2 (Reuters) - JPMorgan Chase & Co(JPM.N)has told prime brokerage clients it will no longer let t","content":"<p>Nov 2 (Reuters) - JPMorgan Chase &amp; Co(JPM.N)has told prime brokerage clients it will no longer let them buy certain U.S. cannabis-related securities beginning Nov. 8, according to a letter seen by Reuters.</p><p><blockquote>路透11月2日-摩根大通(JPM.N)已告诉大宗经纪客户，从11月8日开始，将不再允许他们购买某些美国大麻相关证券。</blockquote></p><p> The move follows similar actions by other banks, including&nbsp;Credit Suisse, after the high-profile&nbsp;collapse&nbsp;of private fund Archegos Capital this year left several banks nursing&nbsp;losses.</p><p><blockquote>此前，包括瑞士信贷在内的其他银行也采取了类似行动，此前私募基金Archegos Capital今年高调倒闭，导致多家银行遭受损失。</blockquote></p><p> The saga drew regulatory scrutiny and prompted banks across Wall Street to review how much risk they are prepared to take on in their prime brokerage businesses.</p><p><blockquote>这一事件引起了监管机构的审查，并促使华尔街的银行审查他们准备在大宗经纪业务中承担多少风险。</blockquote></p><p> While many states have legalized the medical or recreational use of cannabis, the substance remains illegal under U.S. federal law, making it risky for banks to deal with cannabis-related businesses.</p><p><blockquote>尽管许多州已将大麻的医疗或娱乐用途合法化，但根据美国联邦法律，该物质仍然是非法的，这使得银行处理大麻相关业务存在风险。</blockquote></p><p> \"J.P. Morgan (JPMS) has introduced a framework that is designed to comply with U.S. money laundering laws and regulations by restricting certain activities in the securities of U.S. Marijuana Related Businesses,\" the bank wrote to clients.</p><p><blockquote>“摩根大通（JPMS）推出了一个框架，旨在通过限制美国大麻相关企业证券的某些活动来遵守美国洗钱法律法规，”该银行在给客户的信中写道。</blockquote></p><p> As of Nov. 8, the bank will not allow new purchases or short positions in the related businesses, but clients with existing positions will be allowed to liquidate them, it said.</p><p><blockquote>该银行表示，自11月8日起，该银行将不允许在相关业务中进行新的购买或空头头寸，但现有头寸的客户将被允许清算。</blockquote></p><p> The restrictions apply to companies with U.S. operations that are not listed on the Nasdaq, the New York Stock Exchange or the Toronto Stock Exchange and have a \"direct nexus to marijuana-related activities.\"</p><p><blockquote>这些限制适用于在美国开展业务、未在纳斯达克、纽约证券交易所或多伦多证券交易所上市且“与大麻相关活动有直接关系”的公司。</blockquote></p><p> Nasdaq and NYSE allow certain cannabis-related companies -- including Canadian companies that do not sell cannabis in the United States - to list their shares, but will not list companies involved in the direct cultivation or sales of the marijuana plant.</p><p><blockquote>纳斯达克和纽约证券交易所允许某些大麻相关公司（包括不在美国销售大麻的加拿大公司）上市其股票，但不会让参与直接种植或销售大麻植物的公司上市。</blockquote></p><p> However, such companies have still found workarounds to trade on over-the-counter exchanges.</p><p><blockquote>然而，这类公司仍然找到了在场外交易所交易的变通办法。</blockquote></p><p> Cowen and Co, another U.S. bank active in the cannabis trading space, in September increased its cash margin requirements for all marijuana related trades on its platform, according to a letter it sent to clients.</p><p><blockquote>另一家活跃于大麻交易领域的美国银行Cowen and Co根据发给客户的一封信，9月份提高了其平台上所有大麻相关交易的现金保证金要求。</blockquote></p><p> A representative for Cowen did not immediately respond to a request for comment.</p><p><blockquote>考恩的代表没有立即回应置评请求。</blockquote></p><p> Some investors have blamed recent selloffs in U.S. cannabis stocks on banks backing away from the sector and the new restrictions at JPMorgan and Cowen could add to the pressure.</p><p><blockquote>一些投资者将最近美国大麻股票的抛售归咎于银行退出该行业，而摩根大通和考恩的新限制可能会加剧压力。</blockquote></p><p> The MSOS exchange-traded fund , which tracks U.S. marijuana stocks, has halved in value since hitting a peak in February.</p><p><blockquote>追踪美国大麻股票的MSOS交易所交易基金自2月份达到峰值以来，其价值已减半。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPMorgan to restrict trading of some U.S. cannabis stocks<blockquote>摩根大通将限制部分美国大麻股票的交易</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPMorgan to restrict trading of some U.S. cannabis stocks<blockquote>摩根大通将限制部分美国大麻股票的交易</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-03 08:29</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nov 2 (Reuters) - JPMorgan Chase &amp; Co(JPM.N)has told prime brokerage clients it will no longer let them buy certain U.S. cannabis-related securities beginning Nov. 8, according to a letter seen by Reuters.</p><p><blockquote>路透11月2日-摩根大通(JPM.N)已告诉大宗经纪客户，从11月8日开始，将不再允许他们购买某些美国大麻相关证券。</blockquote></p><p> The move follows similar actions by other banks, including&nbsp;Credit Suisse, after the high-profile&nbsp;collapse&nbsp;of private fund Archegos Capital this year left several banks nursing&nbsp;losses.</p><p><blockquote>此前，包括瑞士信贷在内的其他银行也采取了类似行动，此前私募基金Archegos Capital今年高调倒闭，导致多家银行遭受损失。</blockquote></p><p> The saga drew regulatory scrutiny and prompted banks across Wall Street to review how much risk they are prepared to take on in their prime brokerage businesses.</p><p><blockquote>这一事件引起了监管机构的审查，并促使华尔街的银行审查他们准备在大宗经纪业务中承担多少风险。</blockquote></p><p> While many states have legalized the medical or recreational use of cannabis, the substance remains illegal under U.S. federal law, making it risky for banks to deal with cannabis-related businesses.</p><p><blockquote>尽管许多州已将大麻的医疗或娱乐用途合法化，但根据美国联邦法律，该物质仍然是非法的，这使得银行处理大麻相关业务存在风险。</blockquote></p><p> \"J.P. Morgan (JPMS) has introduced a framework that is designed to comply with U.S. money laundering laws and regulations by restricting certain activities in the securities of U.S. Marijuana Related Businesses,\" the bank wrote to clients.</p><p><blockquote>“摩根大通（JPMS）推出了一个框架，旨在通过限制美国大麻相关企业证券的某些活动来遵守美国洗钱法律法规，”该银行在给客户的信中写道。</blockquote></p><p> As of Nov. 8, the bank will not allow new purchases or short positions in the related businesses, but clients with existing positions will be allowed to liquidate them, it said.</p><p><blockquote>该银行表示，自11月8日起，该银行将不允许在相关业务中进行新的购买或空头头寸，但现有头寸的客户将被允许清算。</blockquote></p><p> The restrictions apply to companies with U.S. operations that are not listed on the Nasdaq, the New York Stock Exchange or the Toronto Stock Exchange and have a \"direct nexus to marijuana-related activities.\"</p><p><blockquote>这些限制适用于在美国开展业务、未在纳斯达克、纽约证券交易所或多伦多证券交易所上市且“与大麻相关活动有直接关系”的公司。</blockquote></p><p> Nasdaq and NYSE allow certain cannabis-related companies -- including Canadian companies that do not sell cannabis in the United States - to list their shares, but will not list companies involved in the direct cultivation or sales of the marijuana plant.</p><p><blockquote>纳斯达克和纽约证券交易所允许某些大麻相关公司（包括不在美国销售大麻的加拿大公司）上市其股票，但不会让参与直接种植或销售大麻植物的公司上市。</blockquote></p><p> However, such companies have still found workarounds to trade on over-the-counter exchanges.</p><p><blockquote>然而，这类公司仍然找到了在场外交易所交易的变通办法。</blockquote></p><p> Cowen and Co, another U.S. bank active in the cannabis trading space, in September increased its cash margin requirements for all marijuana related trades on its platform, according to a letter it sent to clients.</p><p><blockquote>另一家活跃于大麻交易领域的美国银行Cowen and Co根据发给客户的一封信，9月份提高了其平台上所有大麻相关交易的现金保证金要求。</blockquote></p><p> A representative for Cowen did not immediately respond to a request for comment.</p><p><blockquote>考恩的代表没有立即回应置评请求。</blockquote></p><p> Some investors have blamed recent selloffs in U.S. cannabis stocks on banks backing away from the sector and the new restrictions at JPMorgan and Cowen could add to the pressure.</p><p><blockquote>一些投资者将最近美国大麻股票的抛售归咎于银行退出该行业，而摩根大通和考恩的新限制可能会加剧压力。</blockquote></p><p> The MSOS exchange-traded fund , which tracks U.S. marijuana stocks, has halved in value since hitting a peak in February.</p><p><blockquote>追踪美国大麻股票的MSOS交易所交易基金自2月份达到峰值以来，其价值已减半。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/finance/exclusive-jpmorgan-restrict-trading-us-cannabis-stocks-letter-2021-11-02/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JPM":"摩根大通"},"source_url":"https://www.reuters.com/business/finance/exclusive-jpmorgan-restrict-trading-us-cannabis-stocks-letter-2021-11-02/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166690474","content_text":"Nov 2 (Reuters) - JPMorgan Chase & Co(JPM.N)has told prime brokerage clients it will no longer let them buy certain U.S. cannabis-related securities beginning Nov. 8, according to a letter seen by Reuters.\nThe move follows similar actions by other banks, including Credit Suisse, after the high-profile collapse of private fund Archegos Capital this year left several banks nursing losses.\nThe saga drew regulatory scrutiny and prompted banks across Wall Street to review how much risk they are prepared to take on in their prime brokerage businesses.\nWhile many states have legalized the medical or recreational use of cannabis, the substance remains illegal under U.S. federal law, making it risky for banks to deal with cannabis-related businesses.\n\"J.P. Morgan (JPMS) has introduced a framework that is designed to comply with U.S. money laundering laws and regulations by restricting certain activities in the securities of U.S. Marijuana Related Businesses,\" the bank wrote to clients.\nAs of Nov. 8, the bank will not allow new purchases or short positions in the related businesses, but clients with existing positions will be allowed to liquidate them, it said.\nThe restrictions apply to companies with U.S. operations that are not listed on the Nasdaq, the New York Stock Exchange or the Toronto Stock Exchange and have a \"direct nexus to marijuana-related activities.\"\nNasdaq and NYSE allow certain cannabis-related companies -- including Canadian companies that do not sell cannabis in the United States - to list their shares, but will not list companies involved in the direct cultivation or sales of the marijuana plant.\nHowever, such companies have still found workarounds to trade on over-the-counter exchanges.\nCowen and Co, another U.S. bank active in the cannabis trading space, in September increased its cash margin requirements for all marijuana related trades on its platform, according to a letter it sent to clients.\nA representative for Cowen did not immediately respond to a request for comment.\nSome investors have blamed recent selloffs in U.S. cannabis stocks on banks backing away from the sector and the new restrictions at JPMorgan and Cowen could add to the pressure.\nThe MSOS exchange-traded fund , which tracks U.S. marijuana stocks, has halved in value since hitting a peak in February.","news_type":1,"symbols_score_info":{"JPM":0.9}},"isVote":1,"tweetType":1,"viewCount":988,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840223890,"gmtCreate":1635651314909,"gmtModify":1635651314999,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Anger]&nbsp;[Anger]&nbsp;","listText":"[Anger]&nbsp;[Anger]&nbsp;","text":"[Anger] [Anger]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/840223890","repostId":"1104228860","repostType":4,"isVote":1,"tweetType":1,"viewCount":1199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857525469,"gmtCreate":1635551080739,"gmtModify":1635551080788,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Great]&nbsp;[Great]&nbsp;","listText":"[Great]&nbsp;[Great]&nbsp;","text":"[Great] [Great]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857525469","repostId":"2179424781","repostType":4,"isVote":1,"tweetType":1,"viewCount":467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856462937,"gmtCreate":1635208049702,"gmtModify":1635208050122,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Surprised]&nbsp;[Surprised]&nbsp;","listText":"[Surprised]&nbsp;[Surprised]&nbsp;","text":"[Surprised] [Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856462937","repostId":"1182426097","repostType":4,"isVote":1,"tweetType":1,"viewCount":644,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856206549,"gmtCreate":1635178110579,"gmtModify":1635178110707,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Anger]&nbsp;[Anger]&nbsp;[Anger]&nbsp;<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>","listText":"[Anger]&nbsp;[Anger]&nbsp;[Anger]&nbsp;<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>","text":"[Anger] [Anger] [Anger] $NIO Inc.(NIO)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856206549","isVote":1,"tweetType":1,"viewCount":522,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":851215484,"gmtCreate":1634910503631,"gmtModify":1634910503783,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Cool]&nbsp;[Cool]&nbsp;[Cool]&nbsp;","listText":"[Cool]&nbsp;[Cool]&nbsp;[Cool]&nbsp;","text":"[Cool] [Cool] [Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/851215484","repostId":"1154277407","repostType":4,"repost":{"id":"1154277407","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634910256,"share":"https://www.laohu8.com/m/news/1154277407?lang=zh_CN&edition=full","pubTime":"2021-10-22 21:44","market":"us","language":"en","title":"Tesla soared nearly 1% and reached an all-time high at 903.32<blockquote>特斯拉大涨近1%创903.32历史新高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1154277407","media":"Tiger Newspress","summary":"Tesla soared nearly 1% and reached an all-time high at 903.32.On the morning of October 21st, Tesla","content":"<p>Tesla&nbsp;soared nearly&nbsp;1% and reached an all-time high at&nbsp;903.32.<img src=\"https://static.tigerbbs.com/9efe14c5fd20d7c4f39cc2a21c93b034\" tg-width=\"1039\" tg-height=\"554\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">On the morning of October 21st, Tesla Motors announced its financial results for the third quarter of 2021.</p><p><blockquote>特斯拉飙升近1%，达到903.32的历史新高。10月21日早间，特斯拉公布2021年第三季度财务业绩。</blockquote></p><p> The financial report shows that Tesla Motors's third-quarter revenue was 13.757 billion US dollars, a year-on-year increase of 57%; The net profit attributable to ordinary shareholders was US $1.618 billion, a year-on-year increase of 389%; Diluted earnings per share was $1.44, compared with $0.27 in the same period last year.</p><p><blockquote>财报显示，特斯拉第三季度营收137.57亿美元，同比增长57%；归属于普通股股东的净利润16.18亿美元，同比增长389%；摊薄后每股收益为1.44美元，上年同期为0.27美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla soared nearly 1% and reached an all-time high at 903.32<blockquote>特斯拉大涨近1%创903.32历史新高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla soared nearly 1% and reached an all-time high at 903.32<blockquote>特斯拉大涨近1%创903.32历史新高</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-22 21:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Tesla&nbsp;soared nearly&nbsp;1% and reached an all-time high at&nbsp;903.32.<img src=\"https://static.tigerbbs.com/9efe14c5fd20d7c4f39cc2a21c93b034\" tg-width=\"1039\" tg-height=\"554\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">On the morning of October 21st, Tesla Motors announced its financial results for the third quarter of 2021.</p><p><blockquote>特斯拉飙升近1%，达到903.32的历史新高。10月21日早间，特斯拉公布2021年第三季度财务业绩。</blockquote></p><p> The financial report shows that Tesla Motors's third-quarter revenue was 13.757 billion US dollars, a year-on-year increase of 57%; The net profit attributable to ordinary shareholders was US $1.618 billion, a year-on-year increase of 389%; Diluted earnings per share was $1.44, compared with $0.27 in the same period last year.</p><p><blockquote>财报显示，特斯拉第三季度营收137.57亿美元，同比增长57%；归属于普通股股东的净利润16.18亿美元，同比增长389%；摊薄后每股收益为1.44美元，上年同期为0.27美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154277407","content_text":"Tesla soared nearly 1% and reached an all-time high at 903.32.On the morning of October 21st, Tesla Motors announced its financial results for the third quarter of 2021.\nThe financial report shows that Tesla Motors's third-quarter revenue was 13.757 billion US dollars, a year-on-year increase of 57%; The net profit attributable to ordinary shareholders was US $1.618 billion, a year-on-year increase of 389%; Diluted earnings per share was $1.44, compared with $0.27 in the same period last year.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":671,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":851990036,"gmtCreate":1634862421328,"gmtModify":1634862421422,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Eye]&nbsp;[Eye]&nbsp;","listText":"[Eye]&nbsp;[Eye]&nbsp;","text":"[Eye] [Eye]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/851990036","repostId":"2177462128","repostType":4,"isVote":1,"tweetType":1,"viewCount":927,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853108068,"gmtCreate":1634777457115,"gmtModify":1634777669510,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Sly]&nbsp;[Sly]&nbsp;","listText":"[Sly]&nbsp;[Sly]&nbsp;","text":"[Sly] [Sly]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/853108068","repostId":"2177314294","repostType":4,"isVote":1,"tweetType":1,"viewCount":969,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":857525469,"gmtCreate":1635551080739,"gmtModify":1635551080788,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Great]&nbsp;[Great]&nbsp;","listText":"[Great]&nbsp;[Great]&nbsp;","text":"[Great] [Great]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857525469","repostId":"2179424781","repostType":4,"isVote":1,"tweetType":1,"viewCount":467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873181408,"gmtCreate":1636883721018,"gmtModify":1636883721018,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Surprised]&nbsp;[Surprised]&nbsp;","listText":"[Surprised]&nbsp;[Surprised]&nbsp;","text":"[Surprised] [Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873181408","repostId":"1103944030","repostType":4,"isVote":1,"tweetType":1,"viewCount":2623,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879741980,"gmtCreate":1636779524101,"gmtModify":1636779524190,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Miser]&nbsp;[Miser]&nbsp;","listText":"[Miser]&nbsp;[Miser]&nbsp;","text":"[Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879741980","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2874,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844842615,"gmtCreate":1636419001309,"gmtModify":1636419001466,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Surprised]&nbsp;[Surprised]&nbsp;","listText":"[Surprised]&nbsp;[Surprised]&nbsp;","text":"[Surprised] [Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/844842615","repostId":"1104683977","repostType":4,"repost":{"id":"1104683977","kind":"news","pubTimestamp":1636418694,"share":"https://www.laohu8.com/m/news/1104683977?lang=zh_CN&edition=full","pubTime":"2021-11-09 08:44","market":"us","language":"en","title":"Short squeezes are pushing these stocks to the moon<blockquote>轧空正在将这些股票推向月球</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1104683977","media":"CNN","summary":"New York (CNN Business)The individual investor army on Reddit that helped push GameStop and AMC to u","content":"<p><a href=\"https://laohu8.com/S/NWY\">New York</a> (CNN Business)The individual investor army on Reddit that helped push <a href=\"https://laohu8.com/S/GME\">GameStop</a> and AMC to unprecedented heights earlier this year has found some more companies to rally around.</p><p><blockquote><a href=\"https://laohu8.com/S/NWY\">纽约</a>（CNN商业）Reddit上的个人投资者大军帮助推动了<a href=\"https://laohu8.com/S/GME\">游戏驿站</a>今年早些时候，AMC达到了前所未有的高度，并找到了更多公司的支持。</blockquote></p><p> Several stocks that have enjoyed extraordinary pops lately, such as <a href=\"https://laohu8.com/S/CAR\">Avis Budget</a> (<a href=\"https://laohu8.com/S/00699\">CAR</a>) and Bed Bath &amp; Beyond (BBBY), have become so-called meme stocks that many professional investors have bet against ... and have gotten burned for because of what's known as a short squeeze.</p><p><blockquote>最近表现出色的几只股票，例如<a href=\"https://laohu8.com/S/CAR\">预算意见</a>(<a href=\"https://laohu8.com/S/00699\">车</a>）和Bed Bath&amp;Beyond(BBBY)已成为许多专业投资者做空的所谓模因股票……并因为所谓的空头挤压而被烧伤。</blockquote></p><p> Avis Budget reported solid earnings last week. But the strength of the stock's 108% surge the day after reporting results surprised many. Shares were up as much as 218% at <a href=\"https://laohu8.com/S/AONE.U\">one</a> point.</p><p><blockquote>Avis Budget上周公布了稳健的收益。但该股在公布业绩后第二天飙升108%，令许多人感到惊讶。股价上涨218%<a href=\"https://laohu8.com/S/AONE.U\">一</a>点。</blockquote></p><p> Bed Bath and Beyond skyrocketed nearly 50% in a matter of a few days last week after announcing a partnership to sell some of its products at grocery store chain <a href=\"https://laohu8.com/S/KR\">Kroger</a> (KR).</p><p><blockquote>Bed Bath and Beyond上周宣布合作在杂货店连锁店销售其部分产品后，股价在几天内飙升了近50%<a href=\"https://laohu8.com/S/KR\">克罗格</a>（KR）。</blockquote></p><p> Both Avis Budget and Bed Bath &amp; Beyond have something in common with AMC (AMC) and GameStop (GME).</p><p><blockquote>Avis Budget和Bed Bath&amp;Beyond都与AMC(AMC)和游戏驿站(GME)有一些共同点。</blockquote></p><p> All of these stocks, along with other meme darlings such as <a href=\"https://laohu8.com/S/BBRY\">BlackBerry</a> (BB), electric van maker <a href=\"https://laohu8.com/S/WKHS\">Workhorse</a> (WKHS) and cannabis company Sundial Growers (SNDL), have been targets of so-called short sellers.</p><p><blockquote>所有这些股票，以及其他迷因宠儿，例如<a href=\"https://laohu8.com/S/BBRY\">黑莓</a>(BB)，电动货车制造商<a href=\"https://laohu8.com/S/WKHS\">老黄牛</a>(WKHS)和大麻公司Sundial Growers(SNDL)一直是所谓卖空者的目标。</blockquote></p><p> More than 20% of the shares of Avis Budget and Bed Bath &amp; Beyond are being held by short sellers, aka shorts.</p><p><blockquote>Avis Budget和Bed Bath&amp;Beyond超过20%的股份由卖空者（又名空头）持有。</blockquote></p><p> Shorts, often big hedge funds and other large institutional firms, will borrow a stock and sell it with the hopes that the price will fall and they can buy it back for less. The short seller then pockets the difference between what they sold at and the repurchase price.</p><p><blockquote>空头，通常是大型对冲基金和其他大型机构公司，会借入股票并出售，希望价格会下跌，然后他们可以以更低的价格回购。然后，卖空者将出售价格与回购价格之间的差额收入囊中。</blockquote></p><p> So say a short sells a borrowed stock when it's trading at $20 and it falls to $10. If the short seller buys the stock back at $10 and returns it to the lender, they make a $10 profit. It's known as covering their short position.</p><p><blockquote>比方说，当一只借来的股票的交易价格为20美元，然后跌至10美元时，卖空者卖出了该股票。如果卖空者以10美元的价格回购股票并将其返还给贷方，他们将获得10美元的利润。这就是所谓的回补空头头寸。</blockquote></p><p> But here's where short sellers can run into trouble. If a stock that's being shorted starts to go up for some reason — such as a good earnings report or news of a strategic partnership — short sellers may be forced to buy back shares en masse or risk incurring massive losses.</p><p><blockquote>但这就是卖空者可能遇到麻烦的地方。如果被做空的股票由于某种原因（例如良好的收益报告或战略合作伙伴关系的消息）开始上涨，卖空者可能会被迫集体回购股票，否则可能会面临遭受巨大损失的风险。</blockquote></p><p> Back to the $20 short seller example, if the company reports good news and the stock goes up to $30, the short seller is looking at a potential $10 loss if they cover at the price. The losses increase as the stock heads higher. If it hits $40, that's a $20 loss, and so on — for every share they've shorted.</p><p><blockquote>回到20美元卖空者的例子，如果公司报告好消息并且股价上涨至30美元，那么卖空者如果按该价格回补，可能会损失10美元。随着股价走高，损失也会增加。如果价格达到40美元，他们每做空一股，就会损失20美元，依此类推。</blockquote></p><p> Plus, short sellers have to eventually return the shares they've borrowed. So if they wait too long to cover the short position, they could face major losses. The so-called apes on Reddit have figured this out.</p><p><blockquote>此外，卖空者最终必须归还他们借入的股票。因此，如果他们等待太久才回补空头头寸，他们可能会面临重大损失。Reddit上所谓的猿类已经明白了这一点。</blockquote></p><p> \"This is what a short squeeze looks like,\" wrote one Reddit user last week about Avis Budget. \"Good (nee, STELLAR) earnings caused sudden and hard upward price movement ... No recourse other than to cover.\"</p><p><blockquote>“这就是轧空的样子，”一位Reddit用户上周在谈到Avis Budget时写道。“良好的（nee，恒星）收益导致价格突然大幅上涨……除了弥补之外没有其他追索权。”</blockquote></p><p> That's why fans of stocks like GameStop, AMC and more recently Avis Budget and Bed Bath &amp; Beyond aggressively call for retail traders to start buying heavily shorted stocks to push them even higher.</p><p><blockquote>这就是为什么游戏驿站、AMC以及最近的Avis Budget和Bed Bath&amp;Beyond等股票的粉丝积极看涨期权，要求散户交易者开始购买严重做空的股票，以推高它们。</blockquote></p><p> They realize that they are inflicting damage on the short sellers by doing so. But that helps push the shares even higher since the short sellers have to start joining the buying frenzy too.</p><p><blockquote>他们意识到这样做是在给卖空者造成损害。但这有助于推高股价，因为卖空者也必须开始加入购买狂潮。</blockquote></p><p> \"Short Squeeze Stocks Season is Back!\" declared one poster on Reddit in a video last week, referring specifically to <a href=\"https://laohu8.com/S/BB\">BlackBerry</a>, Avis Budget, Bed Bath &amp; Beyond, AMC and GameStop.</p><p><blockquote>“逼空股票季节又回来了！”上周在Reddit上的一段视频中宣布了一张海报，特别是指<a href=\"https://laohu8.com/S/BB\">黑莓</a>、Avis Budget、Bed Bath&amp;Beyond、AMC和游戏驿站。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Short squeezes are pushing these stocks to the moon<blockquote>轧空正在将这些股票推向月球</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShort squeezes are pushing these stocks to the moon<blockquote>轧空正在将这些股票推向月球</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">CNN</strong><span class=\"h-time small\">2021-11-09 08:44</span>\n</p>\n</h4>\n</header>\n<article>\n<p><a href=\"https://laohu8.com/S/NWY\">New York</a> (CNN Business)The individual investor army on Reddit that helped push <a href=\"https://laohu8.com/S/GME\">GameStop</a> and AMC to unprecedented heights earlier this year has found some more companies to rally around.</p><p><blockquote><a href=\"https://laohu8.com/S/NWY\">纽约</a>（CNN商业）Reddit上的个人投资者大军帮助推动了<a href=\"https://laohu8.com/S/GME\">游戏驿站</a>今年早些时候，AMC达到了前所未有的高度，并找到了更多公司的支持。</blockquote></p><p> Several stocks that have enjoyed extraordinary pops lately, such as <a href=\"https://laohu8.com/S/CAR\">Avis Budget</a> (<a href=\"https://laohu8.com/S/00699\">CAR</a>) and Bed Bath &amp; Beyond (BBBY), have become so-called meme stocks that many professional investors have bet against ... and have gotten burned for because of what's known as a short squeeze.</p><p><blockquote>最近表现出色的几只股票，例如<a href=\"https://laohu8.com/S/CAR\">预算意见</a>(<a href=\"https://laohu8.com/S/00699\">车</a>）和Bed Bath&amp;Beyond(BBBY)已成为许多专业投资者做空的所谓模因股票……并因为所谓的空头挤压而被烧伤。</blockquote></p><p> Avis Budget reported solid earnings last week. But the strength of the stock's 108% surge the day after reporting results surprised many. Shares were up as much as 218% at <a href=\"https://laohu8.com/S/AONE.U\">one</a> point.</p><p><blockquote>Avis Budget上周公布了稳健的收益。但该股在公布业绩后第二天飙升108%，令许多人感到惊讶。股价上涨218%<a href=\"https://laohu8.com/S/AONE.U\">一</a>点。</blockquote></p><p> Bed Bath and Beyond skyrocketed nearly 50% in a matter of a few days last week after announcing a partnership to sell some of its products at grocery store chain <a href=\"https://laohu8.com/S/KR\">Kroger</a> (KR).</p><p><blockquote>Bed Bath and Beyond上周宣布合作在杂货店连锁店销售其部分产品后，股价在几天内飙升了近50%<a href=\"https://laohu8.com/S/KR\">克罗格</a>（KR）。</blockquote></p><p> Both Avis Budget and Bed Bath &amp; Beyond have something in common with AMC (AMC) and GameStop (GME).</p><p><blockquote>Avis Budget和Bed Bath&amp;Beyond都与AMC(AMC)和游戏驿站(GME)有一些共同点。</blockquote></p><p> All of these stocks, along with other meme darlings such as <a href=\"https://laohu8.com/S/BBRY\">BlackBerry</a> (BB), electric van maker <a href=\"https://laohu8.com/S/WKHS\">Workhorse</a> (WKHS) and cannabis company Sundial Growers (SNDL), have been targets of so-called short sellers.</p><p><blockquote>所有这些股票，以及其他迷因宠儿，例如<a href=\"https://laohu8.com/S/BBRY\">黑莓</a>(BB)，电动货车制造商<a href=\"https://laohu8.com/S/WKHS\">老黄牛</a>(WKHS)和大麻公司Sundial Growers(SNDL)一直是所谓卖空者的目标。</blockquote></p><p> More than 20% of the shares of Avis Budget and Bed Bath &amp; Beyond are being held by short sellers, aka shorts.</p><p><blockquote>Avis Budget和Bed Bath&amp;Beyond超过20%的股份由卖空者（又名空头）持有。</blockquote></p><p> Shorts, often big hedge funds and other large institutional firms, will borrow a stock and sell it with the hopes that the price will fall and they can buy it back for less. The short seller then pockets the difference between what they sold at and the repurchase price.</p><p><blockquote>空头，通常是大型对冲基金和其他大型机构公司，会借入股票并出售，希望价格会下跌，然后他们可以以更低的价格回购。然后，卖空者将出售价格与回购价格之间的差额收入囊中。</blockquote></p><p> So say a short sells a borrowed stock when it's trading at $20 and it falls to $10. If the short seller buys the stock back at $10 and returns it to the lender, they make a $10 profit. It's known as covering their short position.</p><p><blockquote>比方说，当一只借来的股票的交易价格为20美元，然后跌至10美元时，卖空者卖出了该股票。如果卖空者以10美元的价格回购股票并将其返还给贷方，他们将获得10美元的利润。这就是所谓的回补空头头寸。</blockquote></p><p> But here's where short sellers can run into trouble. If a stock that's being shorted starts to go up for some reason — such as a good earnings report or news of a strategic partnership — short sellers may be forced to buy back shares en masse or risk incurring massive losses.</p><p><blockquote>但这就是卖空者可能遇到麻烦的地方。如果被做空的股票由于某种原因（例如良好的收益报告或战略合作伙伴关系的消息）开始上涨，卖空者可能会被迫集体回购股票，否则可能会面临遭受巨大损失的风险。</blockquote></p><p> Back to the $20 short seller example, if the company reports good news and the stock goes up to $30, the short seller is looking at a potential $10 loss if they cover at the price. The losses increase as the stock heads higher. If it hits $40, that's a $20 loss, and so on — for every share they've shorted.</p><p><blockquote>回到20美元卖空者的例子，如果公司报告好消息并且股价上涨至30美元，那么卖空者如果按该价格回补，可能会损失10美元。随着股价走高，损失也会增加。如果价格达到40美元，他们每做空一股，就会损失20美元，依此类推。</blockquote></p><p> Plus, short sellers have to eventually return the shares they've borrowed. So if they wait too long to cover the short position, they could face major losses. The so-called apes on Reddit have figured this out.</p><p><blockquote>此外，卖空者最终必须归还他们借入的股票。因此，如果他们等待太久才回补空头头寸，他们可能会面临重大损失。Reddit上所谓的猿类已经明白了这一点。</blockquote></p><p> \"This is what a short squeeze looks like,\" wrote one Reddit user last week about Avis Budget. \"Good (nee, STELLAR) earnings caused sudden and hard upward price movement ... No recourse other than to cover.\"</p><p><blockquote>“这就是轧空的样子，”一位Reddit用户上周在谈到Avis Budget时写道。“良好的（nee，恒星）收益导致价格突然大幅上涨……除了弥补之外没有其他追索权。”</blockquote></p><p> That's why fans of stocks like GameStop, AMC and more recently Avis Budget and Bed Bath &amp; Beyond aggressively call for retail traders to start buying heavily shorted stocks to push them even higher.</p><p><blockquote>这就是为什么游戏驿站、AMC以及最近的Avis Budget和Bed Bath&amp;Beyond等股票的粉丝积极看涨期权，要求散户交易者开始购买严重做空的股票，以推高它们。</blockquote></p><p> They realize that they are inflicting damage on the short sellers by doing so. But that helps push the shares even higher since the short sellers have to start joining the buying frenzy too.</p><p><blockquote>他们意识到这样做是在给卖空者造成损害。但这有助于推高股价，因为卖空者也必须开始加入购买狂潮。</blockquote></p><p> \"Short Squeeze Stocks Season is Back!\" declared one poster on Reddit in a video last week, referring specifically to <a href=\"https://laohu8.com/S/BB\">BlackBerry</a>, Avis Budget, Bed Bath &amp; Beyond, AMC and GameStop.</p><p><blockquote>“逼空股票季节又回来了！”上周在Reddit上的一段视频中宣布了一张海报，特别是指<a href=\"https://laohu8.com/S/BB\">黑莓</a>、Avis Budget、Bed Bath&amp;Beyond、AMC和游戏驿站。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://edition.cnn.com/2021/11/08/investing/short-squeeze-stocks/index.html\">CNN</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CAR":"安飞士","KR":"克罗格","BBBY":"Bed Bath & Beyond, Inc.","GME":"游戏驿站","AMC":"AMC院线"},"source_url":"https://edition.cnn.com/2021/11/08/investing/short-squeeze-stocks/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104683977","content_text":"New York (CNN Business)The individual investor army on Reddit that helped push GameStop and AMC to unprecedented heights earlier this year has found some more companies to rally around.\nSeveral stocks that have enjoyed extraordinary pops lately, such as Avis Budget (CAR) and Bed Bath & Beyond (BBBY), have become so-called meme stocks that many professional investors have bet against ... and have gotten burned for because of what's known as a short squeeze.\nAvis Budget reported solid earnings last week. But the strength of the stock's 108% surge the day after reporting results surprised many. Shares were up as much as 218% at one point.\nBed Bath and Beyond skyrocketed nearly 50% in a matter of a few days last week after announcing a partnership to sell some of its products at grocery store chain Kroger (KR).\nBoth Avis Budget and Bed Bath & Beyond have something in common with AMC (AMC) and GameStop (GME).\nAll of these stocks, along with other meme darlings such as BlackBerry (BB), electric van maker Workhorse (WKHS) and cannabis company Sundial Growers (SNDL), have been targets of so-called short sellers.\nMore than 20% of the shares of Avis Budget and Bed Bath & Beyond are being held by short sellers, aka shorts.\nShorts, often big hedge funds and other large institutional firms, will borrow a stock and sell it with the hopes that the price will fall and they can buy it back for less. The short seller then pockets the difference between what they sold at and the repurchase price.\nSo say a short sells a borrowed stock when it's trading at $20 and it falls to $10. If the short seller buys the stock back at $10 and returns it to the lender, they make a $10 profit. It's known as covering their short position.\nBut here's where short sellers can run into trouble. If a stock that's being shorted starts to go up for some reason — such as a good earnings report or news of a strategic partnership — short sellers may be forced to buy back shares en masse or risk incurring massive losses.\nBack to the $20 short seller example, if the company reports good news and the stock goes up to $30, the short seller is looking at a potential $10 loss if they cover at the price. The losses increase as the stock heads higher. If it hits $40, that's a $20 loss, and so on — for every share they've shorted.\nPlus, short sellers have to eventually return the shares they've borrowed. So if they wait too long to cover the short position, they could face major losses. The so-called apes on Reddit have figured this out.\n\"This is what a short squeeze looks like,\" wrote one Reddit user last week about Avis Budget. \"Good (nee, STELLAR) earnings caused sudden and hard upward price movement ... No recourse other than to cover.\"\nThat's why fans of stocks like GameStop, AMC and more recently Avis Budget and Bed Bath & Beyond aggressively call for retail traders to start buying heavily shorted stocks to push them even higher.\nThey realize that they are inflicting damage on the short sellers by doing so. But that helps push the shares even higher since the short sellers have to start joining the buying frenzy too.\n\"Short Squeeze Stocks Season is Back!\" declared one poster on Reddit in a video last week, referring specifically to BlackBerry, Avis Budget, Bed Bath & Beyond, AMC and GameStop.","news_type":1,"symbols_score_info":{"GME":0.9,"AMC":0.9,"CAR":0.9,"KR":0.9,"BBBY":0.9}},"isVote":1,"tweetType":1,"viewCount":861,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":134680886,"gmtCreate":1622221398045,"gmtModify":1634182672568,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/134680886","repostId":"2138948877","repostType":4,"isVote":1,"tweetType":1,"viewCount":664,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":872913922,"gmtCreate":1637389846629,"gmtModify":1637390296485,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Happy]&nbsp;[Happy]&nbsp;","listText":"[Happy]&nbsp;[Happy]&nbsp;","text":"[Happy] [Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872913922","repostId":"2184842262","repostType":4,"isVote":1,"tweetType":1,"viewCount":2006,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840223890,"gmtCreate":1635651314909,"gmtModify":1635651314999,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"[Anger]&nbsp;[Anger]&nbsp;","listText":"[Anger]&nbsp;[Anger]&nbsp;","text":"[Anger] [Anger]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/840223890","repostId":"1104228860","repostType":4,"isVote":1,"tweetType":1,"viewCount":1199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827293545,"gmtCreate":1634474038017,"gmtModify":1634474137176,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/827293545","repostId":"1169383767","repostType":4,"repost":{"id":"1169383767","kind":"news","pubTimestamp":1634311170,"share":"https://www.laohu8.com/m/news/1169383767?lang=zh_CN&edition=full","pubTime":"2021-10-15 23:19","market":"us","language":"en","title":"Plug Power's Lowered Guidance Lacking Detail, Analyst Says<blockquote>分析师称普拉格能源下调指引缺乏细节</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169383767","media":"TheStreet","summary":"'Details were not provided,' Coker Palmer analyst Vaibhav Vaishnav writes. He has a price target of ","content":"<p>'Details were not provided,' Coker Palmer analyst Vaibhav Vaishnav writes. He has a price target of $13 for the stock, compared to its recent quote of $32.08.</p><p><blockquote>Coker Palmer分析师Vaibhav Vaishnav写道，没有提供细节。他对该股的目标价为13美元，而最近的报价为32.08美元。</blockquote></p><p> While Plug Power&nbsp;shares firmed Friday after the hydrogen technology company’s earnings guidance beat expectations, at least one analyst wanted something else: details.</p><p><blockquote>尽管在氢技术公司的盈利指引超出预期后，普拉格能源股价周五走强，但至少一位分析师想要别的东西：细节。</blockquote></p><p> “Details were not provided,” Vaibhav Vaishnav of Coker Palmer Institutional wrote in a commentary. He sees tough sledding for Plug Power’s stock in the near term, with a price target of $13. He rates Plug Power a sector underperform.</p><p><blockquote>“没有提供细节，”Coker Palmer Institutional的Vaibhav Vaishnav在评论中写道。他预计普拉格能源股价短期内将大幅下跌，目标价为13美元。他将普拉格能源评为表现不佳的行业。</blockquote></p><p> The stock recently traded at $32.13, up 1%.</p><p><blockquote>该股近期交易价格为32.13美元，上涨1%。</blockquote></p><p> Among the details Vaishnav sees as missing: Specifics on the company's $3 billion revenue estimate as well as investments needed to achieve its stated targets.</p><p><blockquote>Vaishnav认为缺失的细节包括：该公司30亿美元收入预期的细节以及实现其既定目标所需的投资。</blockquote></p><p> “The company spoke only about $1 billion in revenue from material handling and $700 million from hydrogen fuel,” Vaishnav said. “We assume the current four segments together total $1 billion, and $700 million is from third-party sales. PLUG also mentioned three gigawatt installed electrolyzers by 2025,\" the analyst wrote.</p><p><blockquote>Vaishnav表示：“该公司仅表示来自物料搬运的收入约为10亿美元，来自氢燃料的收入为7亿美元。”该分析师写道：“我们假设目前四个细分市场的总额为10亿美元，其中7亿美元来自第三方销售。PLUG还提到到2025年将安装3吉瓦的电解槽。”</blockquote></p><p> What's more, Plug Power is targeting 500 Temperature Programmed Desorption (TPD) plants and 1,000 TPD plants by 2025/'28 respectively.</p><p><blockquote>此外，普拉格能源的目标是到2025/28年分别建设500座程序升温脱附(TPD)工厂和1,000座程序升温脱附(TPD)工厂。</blockquote></p><p> \"Each 20 TPD plant costs $100 million, implying $2 billion/$4 billion capex beyond the initial 100 TPD targeted by the end of 2022,\" Viashnav wrote. \"PLUG intends to build a GW factory in Korea and a 2 GW factory in Australia. The HYVIA production facility could cost $200 million.</p><p><blockquote>Viashnav写道：“每座20吨/日的工厂成本为1亿美元，这意味着比2022年底前最初的100吨/日目标还要多20亿美元/40亿美元的资本支出。”“PLUG打算在韩国建造一座GW工厂，在澳大利亚建造一座2 GW工厂。HYVIA生产设施可能耗资2亿美元。</blockquote></p><p> Also lacking additional detail, according to Viashnav: the company's estimates on how much it can make on hydrogen sales.</p><p><blockquote>Viashnav表示，还缺乏更多细节：该公司对氢气销售收入的估计。</blockquote></p><p> “The average purchase price for hydrogen from third parties, the amount of hydrogen lost in storage/transfer and the selling price to internal customers,\" Vaishnav said.</p><p><blockquote>Vaishnav说：“从第三方购买氢气的平均价格、储存/转移过程中损失的氢气量以及向内部客户的销售价格。”</blockquote></p><p> \"The company estimates it can generate 30% gross margins at $6/kilogram, which makes sense to us. But we look for clarity on translation from the $6/kg selling price to an effective price realized of $4/Kg in 2019/’20/1H ‘21.”</p><p><blockquote>“该公司估计，以6美元/公斤的价格可以产生30%的毛利率，这对我们来说是有意义的。但我们希望澄清从6美元/公斤的售价转换为2019年实现的4美元/公斤的有效价格/公斤/20/1 H'21。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Plug Power's Lowered Guidance Lacking Detail, Analyst Says<blockquote>分析师称普拉格能源下调指引缺乏细节</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPlug Power's Lowered Guidance Lacking Detail, Analyst Says<blockquote>分析师称普拉格能源下调指引缺乏细节</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-10-15 23:19</span>\n</p>\n</h4>\n</header>\n<article>\n<p>'Details were not provided,' Coker Palmer analyst Vaibhav Vaishnav writes. He has a price target of $13 for the stock, compared to its recent quote of $32.08.</p><p><blockquote>Coker Palmer分析师Vaibhav Vaishnav写道，没有提供细节。他对该股的目标价为13美元，而最近的报价为32.08美元。</blockquote></p><p> While Plug Power&nbsp;shares firmed Friday after the hydrogen technology company’s earnings guidance beat expectations, at least one analyst wanted something else: details.</p><p><blockquote>尽管在氢技术公司的盈利指引超出预期后，普拉格能源股价周五走强，但至少一位分析师想要别的东西：细节。</blockquote></p><p> “Details were not provided,” Vaibhav Vaishnav of Coker Palmer Institutional wrote in a commentary. He sees tough sledding for Plug Power’s stock in the near term, with a price target of $13. He rates Plug Power a sector underperform.</p><p><blockquote>“没有提供细节，”Coker Palmer Institutional的Vaibhav Vaishnav在评论中写道。他预计普拉格能源股价短期内将大幅下跌，目标价为13美元。他将普拉格能源评为表现不佳的行业。</blockquote></p><p> The stock recently traded at $32.13, up 1%.</p><p><blockquote>该股近期交易价格为32.13美元，上涨1%。</blockquote></p><p> Among the details Vaishnav sees as missing: Specifics on the company's $3 billion revenue estimate as well as investments needed to achieve its stated targets.</p><p><blockquote>Vaishnav认为缺失的细节包括：该公司30亿美元收入预期的细节以及实现其既定目标所需的投资。</blockquote></p><p> “The company spoke only about $1 billion in revenue from material handling and $700 million from hydrogen fuel,” Vaishnav said. “We assume the current four segments together total $1 billion, and $700 million is from third-party sales. PLUG also mentioned three gigawatt installed electrolyzers by 2025,\" the analyst wrote.</p><p><blockquote>Vaishnav表示：“该公司仅表示来自物料搬运的收入约为10亿美元，来自氢燃料的收入为7亿美元。”该分析师写道：“我们假设目前四个细分市场的总额为10亿美元，其中7亿美元来自第三方销售。PLUG还提到到2025年将安装3吉瓦的电解槽。”</blockquote></p><p> What's more, Plug Power is targeting 500 Temperature Programmed Desorption (TPD) plants and 1,000 TPD plants by 2025/'28 respectively.</p><p><blockquote>此外，普拉格能源的目标是到2025/28年分别建设500座程序升温脱附(TPD)工厂和1,000座程序升温脱附(TPD)工厂。</blockquote></p><p> \"Each 20 TPD plant costs $100 million, implying $2 billion/$4 billion capex beyond the initial 100 TPD targeted by the end of 2022,\" Viashnav wrote. \"PLUG intends to build a GW factory in Korea and a 2 GW factory in Australia. The HYVIA production facility could cost $200 million.</p><p><blockquote>Viashnav写道：“每座20吨/日的工厂成本为1亿美元，这意味着比2022年底前最初的100吨/日目标还要多20亿美元/40亿美元的资本支出。”“PLUG打算在韩国建造一座GW工厂，在澳大利亚建造一座2 GW工厂。HYVIA生产设施可能耗资2亿美元。</blockquote></p><p> Also lacking additional detail, according to Viashnav: the company's estimates on how much it can make on hydrogen sales.</p><p><blockquote>Viashnav表示，还缺乏更多细节：该公司对氢气销售收入的估计。</blockquote></p><p> “The average purchase price for hydrogen from third parties, the amount of hydrogen lost in storage/transfer and the selling price to internal customers,\" Vaishnav said.</p><p><blockquote>Vaishnav说：“从第三方购买氢气的平均价格、储存/转移过程中损失的氢气量以及向内部客户的销售价格。”</blockquote></p><p> \"The company estimates it can generate 30% gross margins at $6/kilogram, which makes sense to us. But we look for clarity on translation from the $6/kg selling price to an effective price realized of $4/Kg in 2019/’20/1H ‘21.”</p><p><blockquote>“该公司估计，以6美元/公斤的价格可以产生30%的毛利率，这对我们来说是有意义的。但我们希望澄清从6美元/公斤的售价转换为2019年实现的4美元/公斤的有效价格/公斤/20/1 H'21。”</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/coker-palmer-lack-of-detail-plug-power\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLUG":"普拉格能源"},"source_url":"https://www.thestreet.com/investing/coker-palmer-lack-of-detail-plug-power","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169383767","content_text":"'Details were not provided,' Coker Palmer analyst Vaibhav Vaishnav writes. He has a price target of $13 for the stock, compared to its recent quote of $32.08.\nWhile Plug Power shares firmed Friday after the hydrogen technology company’s earnings guidance beat expectations, at least one analyst wanted something else: details.\n“Details were not provided,” Vaibhav Vaishnav of Coker Palmer Institutional wrote in a commentary. He sees tough sledding for Plug Power’s stock in the near term, with a price target of $13. He rates Plug Power a sector underperform.\nThe stock recently traded at $32.13, up 1%.\nAmong the details Vaishnav sees as missing: Specifics on the company's $3 billion revenue estimate as well as investments needed to achieve its stated targets.\n“The company spoke only about $1 billion in revenue from material handling and $700 million from hydrogen fuel,” Vaishnav said. “We assume the current four segments together total $1 billion, and $700 million is from third-party sales. PLUG also mentioned three gigawatt installed electrolyzers by 2025,\" the analyst wrote.\nWhat's more, Plug Power is targeting 500 Temperature Programmed Desorption (TPD) plants and 1,000 TPD plants by 2025/'28 respectively.\n\"Each 20 TPD plant costs $100 million, implying $2 billion/$4 billion capex beyond the initial 100 TPD targeted by the end of 2022,\" Viashnav wrote. \"PLUG intends to build a GW factory in Korea and a 2 GW factory in Australia. The HYVIA production facility could cost $200 million.\nAlso lacking additional detail, according to Viashnav: the company's estimates on how much it can make on hydrogen sales.\n“The average purchase price for hydrogen from third parties, the amount of hydrogen lost in storage/transfer and the selling price to internal customers,\" Vaishnav said.\n\"The company estimates it can generate 30% gross margins at $6/kilogram, which makes sense to us. But we look for clarity on translation from the $6/kg selling price to an effective price realized of $4/Kg in 2019/’20/1H ‘21.”","news_type":1,"symbols_score_info":{"PLUG":0.9}},"isVote":1,"tweetType":1,"viewCount":667,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":150741278,"gmtCreate":1624929122294,"gmtModify":1633946898854,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/150741278","repostId":"1103175848","repostType":4,"isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120885818,"gmtCreate":1624318995334,"gmtModify":1634007988703,"author":{"id":"3577149952498564","authorId":"3577149952498564","name":"CaiCai99","avatar":"https://static.tigerbbs.com/c59f7b803ae24d48731eeccaef4733dd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577149952498564","idStr":"3577149952498564"},"themes":[],"htmlText":"Like and comment&nbsp;","listText":"Like and comment&nbsp;","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/120885818","repostId":"1148988961","repostType":4,"repost":{"id":"1148988961","kind":"news","pubTimestamp":1624317433,"share":"https://www.laohu8.com/m/news/1148988961?lang=zh_CN&edition=full","pubTime":"2021-06-22 07:17","market":"us","language":"en","title":"Chicken producer Sanderson Farms explores sale<blockquote>鸡肉生产商桑德森农场探索出售</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1148988961","media":"Reuters","summary":"(Reuters) - Chicken producer Sanderson Farms Inc is exploring a sale, according to a source familiar","content":"<p>(Reuters) - Chicken producer Sanderson Farms Inc is exploring a sale, according to a source familiar with the matter, at a time demand for its products is on the rise as restaurants reopen for business.</p><p><blockquote>（路透社）-据一位知情人士透露，鸡肉生产商桑德森农场公司正在考虑出售，目前随着餐馆重新开业，对其产品的需求正在上升。</blockquote></p><p> The company’s shares rose about 9% to $181 after the closing bell.</p><p><blockquote>收盘后，该公司股价上涨约9%，至181美元。</blockquote></p><p> Sanderson Farms has drawn interest from buyers including agricultural investment firm Continental Grain Co, which owns a smaller chicken processor, Wayne Farms, the source said.</p><p><blockquote>消息人士称，桑德森农场吸引了包括农业投资公司大陆谷物公司在内的买家的兴趣，该公司拥有一家规模较小的鸡肉加工商韦恩农场。</blockquote></p><p> The deal would form a company producing about 15% of the country's chicken meat. The second largest company, Pilgrim's Pride Corp, produces about 16%, according to the Wall Street Journalhere, which first reported the news.</p><p><blockquote>这笔交易将成立一家公司，生产该国约15%的鸡肉。据最先报道这一消息的《华尔街日报》报道，第二大公司Pilgrim’s Pride Corp的产量约为16%。</blockquote></p><p> Prices of chicken products, especially those of wings and breasts, have risen as easing restrictions are bringing consumers back to restaurants and more fast-food chains are battling to create fried-chicken sandwiches.</p><p><blockquote>鸡肉产品的价格，尤其是鸡翅和鸡胸肉的价格，已经上涨，因为限制的放松让消费者回到餐馆，更多的快餐连锁店正在努力生产炸鸡三明治。</blockquote></p><p> Last year, Sanderson Farms said it had rejected an unsolicited proposal from Durational Capital Management, a new shareholder, for $142 per share, as it undervalued the company.</p><p><blockquote>去年，Sanderson Farms表示，它拒绝了新股东Durational Capital Management主动提出的每股142美元的提议，因为该提议低估了该公司的价值。</blockquote></p><p> The Laurel, Mississippi-based company has a market share of about $3.5 billion.</p><p><blockquote>这家总部位于密西西比州劳雷尔的公司拥有约35亿美元的市场份额。</blockquote></p><p> Sanderson Farms declined a Reuters request for comment.</p><p><blockquote>桑德森农场拒绝了路透社的置评请求。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chicken producer Sanderson Farms explores sale<blockquote>鸡肉生产商桑德森农场探索出售</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChicken producer Sanderson Farms explores sale<blockquote>鸡肉生产商桑德森农场探索出售</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-06-22 07:17</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Reuters) - Chicken producer Sanderson Farms Inc is exploring a sale, according to a source familiar with the matter, at a time demand for its products is on the rise as restaurants reopen for business.</p><p><blockquote>（路透社）-据一位知情人士透露，鸡肉生产商桑德森农场公司正在考虑出售，目前随着餐馆重新开业，对其产品的需求正在上升。</blockquote></p><p> The company’s shares rose about 9% to $181 after the closing bell.</p><p><blockquote>收盘后，该公司股价上涨约9%，至181美元。</blockquote></p><p> Sanderson Farms has drawn interest from buyers including agricultural investment firm Continental Grain Co, which owns a smaller chicken processor, Wayne Farms, the source said.</p><p><blockquote>消息人士称，桑德森农场吸引了包括农业投资公司大陆谷物公司在内的买家的兴趣，该公司拥有一家规模较小的鸡肉加工商韦恩农场。</blockquote></p><p> The deal would form a company producing about 15% of the country's chicken meat. The second largest company, Pilgrim's Pride Corp, produces about 16%, according to the Wall Street Journalhere, which first reported the news.</p><p><blockquote>这笔交易将成立一家公司，生产该国约15%的鸡肉。据最先报道这一消息的《华尔街日报》报道，第二大公司Pilgrim’s Pride Corp的产量约为16%。</blockquote></p><p> Prices of chicken products, especially those of wings and breasts, have risen as easing restrictions are bringing consumers back to restaurants and more fast-food chains are battling to create fried-chicken sandwiches.</p><p><blockquote>鸡肉产品的价格，尤其是鸡翅和鸡胸肉的价格，已经上涨，因为限制的放松让消费者回到餐馆，更多的快餐连锁店正在努力生产炸鸡三明治。</blockquote></p><p> Last year, Sanderson Farms said it had rejected an unsolicited proposal from Durational Capital Management, a new shareholder, for $142 per share, as it undervalued the company.</p><p><blockquote>去年，Sanderson Farms表示，它拒绝了新股东Durational Capital Management主动提出的每股142美元的提议，因为该提议低估了该公司的价值。</blockquote></p><p> The Laurel, Mississippi-based company has a market share of about $3.5 billion.</p><p><blockquote>这家总部位于密西西比州劳雷尔的公司拥有约35亿美元的市场份额。</blockquote></p><p> Sanderson Farms declined a Reuters request for comment.</p><p><blockquote>桑德森农场拒绝了路透社的置评请求。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/article/sanderson-farms-ma/-chicken-producer-sanderson-farms-explores-sale-source-idUSL3N2O347V\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/article/sanderson-farms-ma/-chicken-producer-sanderson-farms-explores-sale-source-idUSL3N2O347V","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148988961","content_text":"(Reuters) - Chicken producer Sanderson Farms Inc is exploring a sale, according to a source familiar with the matter, at a time demand for its products is on the rise as restaurants reopen for business.\nThe company’s shares rose about 9% to $181 after the closing bell.\nSanderson Farms has drawn interest from buyers including agricultural investment firm Continental Grain Co, which owns a smaller chicken processor, Wayne Farms, the source said.\nThe deal would form a company producing about 15% of the country's chicken meat. The second largest company, Pilgrim's Pride Corp, produces about 16%, according to the Wall Street Journalhere, which first reported the news.\nPrices of chicken products, especially those of wings and breasts, have risen as easing restrictions are bringing consumers back to restaurants and more fast-food chains are battling to create fried-chicken sandwiches.\nLast year, Sanderson Farms said it had rejected an unsolicited proposal from Durational Capital Management, a new shareholder, for $142 per share, as it undervalued the company.\nThe Laurel, Mississippi-based company has a market share of about $3.5 billion.\nSanderson Farms declined a Reuters request for comment.","news_type":1,"symbols_score_info":{"SAFM":0.9}},"isVote":1,"tweetType":1,"viewCount":547,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}